일차성 중추신경계 림프종의 경막 내 Rituximab 치료 2예
Two Cases of Treatment with Intrathecal Rituximab for Primary Central Nervous System Lymphoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin’s lymphoma (NHL), usually composed ofdiffuse large B-cells. Although rituximab is known for its curative effect on B-cell NHL, data on the use of intrathecal rituximab forPCNSL are limited. In this report, we present two patients showing relapsed PCNSL with lymphomatous meningitis. Both patientswere refractory to conventional methotrexate-based intrathecal chemotherapy. However, after intrathecal rituximab with or withoutconventional intrathecal chemotherapy, both patients showed stable disease on magnetic resonance brain imaging and cerebrospinalfluid analysis. There were no serious adverse events during each of 3 and 6 cycles with intrathecal rituximab immunotherapy
Abstract
Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin’s lymphoma (NHL), usually composed ofdiffuse large B-cells. Although rituximab is known for its curative effect on B-cell NHL, data on the use of intrathecal rituximab forPCNSL are limited. In this report, we present two patients showing relapsed PCNSL with lymphomatous meningitis. Both patientswere refractory to conventional methotrexate-based intrathecal chemotherapy. However, after intrathecal rituximab with or withoutconventional intrathecal chemotherapy, both patients showed stable disease on magnetic resonance brain imaging and cerebrospinalfluid analysis. There were no serious adverse events during each of 3 and 6 cycles with intrathecal rituximab immunotherapy
참고문헌 (10)
- Ferreri AJ, "How I treat primary CNS lymphoma", Blood, 118, pp.510~522 (2011)
- Batchelor T, "Primary CNS lymphoma", J Clin Oncol, 24, pp.1281~1288 (2006)
- Dietlein M, "Imaging of central nervous system lymphomas with iodine-123 labeled rituximab", Eur J Haematol, 74, pp.348~352 (2005)
- Ferreri AJ, "Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience", J Clin Oncol, 21, pp.266~272 (2003)
- Rubenstein JL, "Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment", Blood, 101, pp.466~468 (2003)
- Rubenstein JL, "High-dose methotrexate plus rituximab (anti-CD20) monoclonal antibody in the treatment of primary", CNS lymphoma: Society for Neuro Oncology Fourth Annual Meeting (1999)
- Rubenstein JL, "Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma", Blood, 121, pp.745~751 (2013)
- Schulz H, "Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab", Haematologica, 89, pp.753~754 (2004)
- Rubenstein JL, "Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma", J Clin Oncol, 25, pp.1350~1356 (2007)
- 홍성진, "A Successful Treatment of Relapsed Primary CNS Lymphoma Patient with Intraventricular Rituximab Followed by High-Dose Chemotherapy with Autologous Stem Cell Rescue", Yonsei Medical Journal, 50(2), pp.280~283 (2009), 연세대학교의과대학